Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide ... disease in adults with type 2 diabetes and chronic kidney disease. The Danish drugmaker said the approval ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

Related Ozempic shows promise in treating fatty liver disease ... serious chronic diseases," Jorgensen said in a statement. The company said Friday that Jorgenson led Novo Nordisk through "a ...

Novo's Victoza and Ozempic ... chronic disease markets and the history of side effects from cardiometabolic drugs, but it has an immaterial effect on our valuation. We assign Novo Nordisk an ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

Ozempic changed the lives of obesity patients. And then we had to stop prescribing itOpens in new window ] According to the inspection, Novo Nordisk ... living with chronic disease in Ireland.” ...

Deboki: Ozempic is now a bona fide blockbuster. Novo Nordisk reported more than $40 ... clinical trials for treatment in heart, liver, and kidney conditions and a phase three trial for Alzheimers’ ...

The FDA has received reports of at least 20 cases of ileus, including two deaths, among people taking Ozempic. The agency ordered that the drugmaker, Novo Nordisk, add a warning label to the drug ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

The 58-year-old Danish executive has spent his entire career at Novo Nordisk, which he joined 34 years ago. Ozempic, which accounts for 41 percent of Novo Nordisk’s sales, is an injectable ...